Reevaluation of the Frequent Use of PD-1 Checkpoint Inhibitors for Treatment of Glioblastoma

Miller, Alexandra; DeAngelis, Lisa M.

doi:10.1001/jama.2020.5934

Cited by 9 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Diese veränderte Form der Tumorbehandlung, die bei Nachweis neuer Tumorläsionen oder bildmorphologischem Größenprogress nicht einen sofortigen Therapie-, sondern eher einen Strategiewechsel fordert, bringt die Notwendigkeit häufiger inter-und multidisziplinärer Fallbesprechungen (Tumorboards) mit sichauch hier ist unabdingbar und über den langen Verlauf einzelner Patientenhistorien hinweg die kontinuierliche Anwesenheit von (oder zumindest der regelhafte Austausch mit) Palliativmedizinern und darüber hinaus ein adäquates geriatrisches Assessment vonnöten [21,22]. [32,33].…”

Section: Paradebeispiel Zielgerichteterunclassified

Neue Therapien in der Onkologie – Wirkweise und Nebenwirkungen

Panse

2021

Onkologie up2date

View full text Add to dashboard Cite

Section: Paradebeispiel Zielgerichteterunclassified

Neue Therapien in der Onkologie – Wirkweise und Nebenwirkungen

Panse

2021

Onkologie up2date

View full text Add to dashboard Cite

“…3 Vereinfachte Übersicht zum Nebenwirkungsspektrum neuer Therapeutika im Vergleich zu klassischer Chemotherapie. [31,32].…”

Section: Zielstruktur Angiogeneseunclassified

Neue Therapien in der Onkologie – Wirkweise und Nebenwirkungen

Panse¹

2020

Zeitschrift für Palliativmedizin

View full text Add to dashboard Cite

Implantable Microneedle‐Mediated Eradication of Postoperative Tumor Foci Mitigates Glioblastoma Relapse

Zhang,

Fang,

Liu

et al. 2024

Advanced Materials

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) remains incurable despite multimodal treatments after surgical debulking. Almost all patients with GBM relapse within a narrow margin (2–3 cm) of the initial resected lesion due to the unreachable residual cancerous cells. Here, a completely biodegradable microneedle for surgical cavity delivery glioblastoma‐associated macrophages (GAMs)‐activating immune nano‐stimulator that mitigates glioblastoma relapse is reported. The residual tumor lesion‐directed biocompatible microneedle releases the nano‐stimulator and toll‐like receptor 9 agonist in a controlled manner until the microneedles completely degrade over 1 week, efferently induce in situ phonotypic shifting of GAMs from anti‐ to pro‐inflammatory and the tumor recurrence is obviously inhibited. The implantable microneedles offer a significant improvement over conventional transdermal ones, as they are 100% degradable, ensuring safe application within surgical cavities. It is also revealed that the T cells are recruited to the tumor niche as the GAMs initiate anti‐tumor response and eradicate residual GBM cells. Taken together, this work provides a potential strategy for immunomodulating the postoperative tumor niche to mitigate tumor relapse in GBM patients, which may have broad applications in other malignancies with surgical intervention.

show abstract

Reevaluation of the Frequent Use of PD-1 Checkpoint Inhibitors for Treatment of Glioblastoma

Cited by 9 publications

References 19 publications

Neue Therapien in der Onkologie – Wirkweise und Nebenwirkungen

Neue Therapien in der Onkologie – Wirkweise und Nebenwirkungen

Neue Therapien in der Onkologie – Wirkweise und Nebenwirkungen

Implantable Microneedle‐Mediated Eradication of Postoperative Tumor Foci Mitigates Glioblastoma Relapse

Contact Info

Product

Resources

About